Policy Notices

• NIAMS Policy for Acceptance of Clinical Trial Applications and Participation in Parent R01 and R21(Clinical Trial Required) Announcements
  (NOT-AR-21-009)
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  

General Notices

• Pre-Application Webinar for RFA-CA-20-053, Genomic Data Analysis Network: Genomic Data Analysis Center (U24 Clinical Trial Not Allowed)
  (NOT-CA-21-002)
  National Cancer Institute
  

• Notice of Technical Assistance Webinar and Frequently Asked Questions (FAQs) for NHLBI HeartShare RFA-HL-21-015 "Clinical Centers (U01)" and RFA-HL-21-016 "Data Translation Center (U54)"
  (NOT-HL-20-819)
  National Heart, Lung, and Blood Institute
  

• RESCINDED - Consolidated Notice on NIMH Clinical Trials Policies
  (NOT-MH-20-105)
  National Institute of Mental Health
  

• Notice of Clarification to the High-Risk, High-Reward Research Program: Pioneer: RFA-RM-20-011, New Innovator: RFA-RM-20-012, Transformative Research (RFA-RM-20-013, RFA-RM-20-020 & NOT-RM-20-019), and Early Independence (RFA-RM-20-014 & RFA-RM-20-021)
  (NOT-RM-21-004)
  Office of Strategic Coordination (Common Fund)
  

• Request for Information on Processes for NRGR Sample Submission, Access, and Management
  (NOT-MH-21-010)
  National Institute of Mental Health
  

• Request for Information: Data Science Challenges and Opportunities in the Field of Precision Nutrition
  (NOT-RM-21-005)
  Office of Strategic Coordination (Common Fund)
  

Notice of Changes to Funding Opportunities

• Notice of Extension of the Expiration Date of PAR-19-363 "Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional)"
  (NOT-CA-21-001)
  National Cancer Institute
  

• Notice of Correction to RFA-CA-20-047 Glioblastoma Therapeutics Network (GTN) (U19 Clinical Trial Required)"
  (NOT-CA-21-004)
  National Cancer Institute
  

• Notice of Correction to RFA-CA-20-052 Limited Competition: Childhood Cancer Survivor Study (U24 Clinical Trial Required)
  (NOT-CA-21-005)
  National Cancer Institute
  

• Notice to Extend the Expiration Date for PAR-18-433 "NIBIB Exploratory/Developmental Research Grant Program (R21 Clinical Trial Optional)"
  (NOT-EB-20-013)
  National Institute of Biomedical Imaging and Bioengineering
  

• Notice of Change to Receipt Date for RFA-HG-20-014, RFA-HG-20-015, and RFA-HG-20-016: NHGRI Synthetic Nucleic Acid Technology Development FOAs
  (NOT-HG-21-005)
  National Human Genome Research Institute
  

• Notice of Change: Correction of Calendar Months Expected To Be Devoted on RFA-HG-20-044 and RFA-HG-20-047 which are part of the "Impact of Genomic Variation on Function Consortium"
  (NOT-HG-21-012)
  National Human Genome Research Institute
  

• Notice of Extension to PA-18-350, "NIMH Exploratory/Developmental Research Grant (R21 Clinical Trial Not Allowed)"
  (NOT-MH-21-040)
  National Institute of Mental Health
  

• Notice of Early Termination of PAR-18-909, Pre-application for the NIH-Industry Program: Discovering New Therapeutic Uses for Existing Molecules (X02 Clinical Trial Not Allowed)
  (NOT-TR-21-003)
  National Center for Advancing Translational Sciences
  

• Notice of Early Termination of PAR-18-910, Limited Competition for NIH-Industry Program: Discovering New Therapeutic Uses for Existing Molecules (U01 Clinical Trial Required)
  (NOT-TR-21-004)
  National Center for Advancing Translational Sciences
  

Notices of Intent to Publish

• Notice of Intent to Publish a Funding Opportunity Announcement for Aging Effects on Osteoimmunology (Clinical Trials Not Allowed)
  (NOT-AG-20-051)
  National Institute on Aging
  

Funding Opportunities

• Successor-in-Interest (Type 6 Parent Clinical Trial Optional)
  (PA-20-275)
  National Institutes of Health
  John E. Fogarty International Center
  National Center for Advancing Translational Sciences
  National Center for Complementary and Integrative Health
  National Cancer Institute
  National Eye Institute
  National Human Genome Research Institute
  National Heart, Lung, and Blood Institute
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Allergy and Infectious Diseases
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  National Institute of Biomedical Imaging and Bioengineering
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Drug Abuse
  National Institute on Deafness and Other Communication Disorders
  National Institute of Dental and Craniofacial Research
  National Institute of Diabetes and Digestive and Kidney Diseases
  National Institute of Environmental Health Sciences
  National Institute of General Medical Sciences
  National Institute of Mental Health
  National Institute on Minority Health and Health Disparities
  National Institute of Neurological Disorders and Stroke
  National Institute of Nursing Research
  National Library of Medicine
  Office of Behavioral and Social Sciences Research
  Office of Research on Women's Health
  Application Receipt Date(s): A successor-in-interest request must be made before the anticipated start date at the new organization and preferably several months in advance.
  
  

• National Dental Practice-Based Research Network Clinical Trial or Observational Study Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Optional)
  (PAR-20-306)
  National Institute of Dental and Craniofacial Research
  Application Receipt Date(s): New applications: November 19, 2020, February 9, 2021, June 9, 2021, and October 8 2021; February 9, 2022, June 9, 2022, and October 7 2022; February 9 2023, June 9, 2023, by 5:00 PM local time of applicant organization. Resubmission and revision applications: November 19, 2020, March 9, 2021, July 9, 2021, and November 9 2021; March 9, 2022, July 8, 2022, November 9 2022; March 9 2023, July 7, 2023, by 5:00 PM local time of applicant organization.
  
  

• Developmental AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optional)
  (PAR-20-307)
  National Institute of Mental Health
  Application Receipt Date(s): Only accepting applications for the AIDS Application Due Date(s) below.
  
  

• AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optional)
  (PAR-20-308)
  National Institute of Mental Health
  Application Receipt Date(s): Only accepting applications for the AIDS Application Due Date(s)
  
  

• Late-Stage Translation of Biomedical and Behavioral Research Results in Arthritis and Musculoskeletal and Skin Diseases from Academic/Non-profit Lab to Marketplace (SBIR [R43/R44] Clinical Trial Not Allowed)
  (PAR-21-030)
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  Application Receipt Date(s): Standard datesapply The first standard due date for this FOA is January 5, 2021.
  
  

• MD-PhD Training Program in Alzheimer's Disease and Related Dementias and the Behavioral and Social Sciences (T32 Clinical Trial Not Allowed)
  (RFA-AG-21-027)
  National Institute on Aging
  Application Receipt Date(s): February 3, 2021 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  
  

• Coccidioidomycosis Collaborative Research Centers (U19 Clinical Trial Not Allowed)
  (RFA-AI-20-056)
  National Institute of Allergy and Infectious Diseases
  Application Receipt Date(s): February 18, 2021 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  
  

• A Multidisciplinary Approach to Study Vaccine-elicited Immunity and Efficacy against Malaria (U01 Clinical Trial Not Allowed)
  (RFA-AI-20-064)
  National Institute of Allergy and Infectious Diseases
  Application Receipt Date(s): February 8, 2021